Radioimmunotherapy of non-Hodgkin's lymphoma revisited [3]

Journal of Nuclear Medicine

Volumn 46, Issue 2, 2005, Pages 383-384

  Goldenberg, David M ^a   Sharkey, Robert M ^a  

^a GARDEN STATE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD22 ANTIGEN; IBRITUMOMAB TIUXETAN; TOSITUMOMAB I 131; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; YTTRIUM;

ANTIGEN EXPRESSION; BONE MARROW; BONE MARROW TOXICITY; DOSIMETRY; DRUG EFFICACY; DRUG TARGETING; HUMAN; LETTER; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; CLINICAL TRIAL; METHODOLOGY; NOTE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 15844382809     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (13)

1. Britton KE. Radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med. 2004;45:924-925.
2. 131I-tositumomab therapy of previously untreated lymphoma patients. J Nucl Med. 2003;44:457-464.
3. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003;44:465-474.
4. 90Y ibritumomab tiuxetan (Zevalin). Semin Oncol. 2003;30(suppl):6-10.
5. 90Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med. 2003; 44:2000-2018.
6. 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med. 2003;44:260-268.
7. Kaminski M, Estes J, Tuck M, et al. Iodine I 131 tositumomab therapy for previously untreated follicular lymphoma [abstract]. Proc Am Soc Clin Oncol. 2000;19:5a.
8. 131I-labeled anti-carcinoembryonic antigen antibodies. Cancer. 1997;80(suppl):2749-2753.
9. O'Donoghue JA, Baidoo N, Deland D, Welt S, Divgi CR, Sgouros G. Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy. Cancer Biother Radiopharm. 2002;17:435-443.
10. 90Y-antibody therapy. J Nucl Med. 2002;43:1245-1253.
11. DeNardo G, Yuan A, Goldstein D, et al. Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs. Cancer Biother Radiopharm. 2003;18:231-237.
12. Siegel JA, Yeldell D, Goldenberg DM, et al. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med. 2003;44:67-76.
13. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463.